What Abbott's latest 10-Q says: 9 signals
Abbott filed its latest 10-Q with the SEC on Jul 28, 2026. It discusses capex increase, cost reduction and inflation impact.
Public (ABT)Software Development10,000+ employeesabbott.comLinkedIn
- Filed
- Jul 28, 2026
- Filings
- 2
- Signals
- 14
10-Q · latest 10
What Abbott's 10-Q filings say
- SEC EDGAR
10-Q
Filed · 9 signals
Abbott completes $20.6B acquisition of Exact Sciences, driving massive integration costs.
The acquisition, funded by $20B in new debt, has increased SG&A expenses by $934M (30.3%) due to integration costs and R&D by $167M (22.9%).
$20.6B
Acquisition cost for Exact Sciences
30.3%
Q2 increase in SG&A expenses
Abbott completes $20.6B acquisition of Exact Sciences, funded by $20B in new debt.
The acquisition establishes Abbott in the cancer diagnostics market but introduces significant integration costs, debt service, and operational complexity.
$20.6B
Total acquisition cost for Exact Sciences
Abbott's $495M legal verdict related to infant formula quality was affirmed on appeal.
A Missouri Court of Appeals upheld a $495 million verdict against Abbott concerning claims its preterm infant formula products led to necrotizing enterocolitis.
$495M
Damages awarded in the 'Gill' infant formula lawsuit, affirmed on appeal
SG&A expenses surge 30.3% ($934M) in Q2 due to acquisition integration and higher legal reserves.
The significant increase in operating expenses, driven by the Exact Sciences integration and legal costs, puts pressure on profitability.
$934M
Increase in SG&A expenses in Q2 2026
30.3%
YoY increase in SG&A expenses in Q2 2026
Court upholds $495M verdict against Abbott in infant formula lawsuit, with more cases pending.
A Missouri Court of Appeals affirmed a $495M verdict related to infant formula products, and the company is involved in numerous similar lawsuits.
$495M
Damages awarded in Gill v. Abbott lawsuit, affirmed on appeal
Abbott launches new Libre® Duo biowearable in Europe after securing CE Mark in May 2026.
This includes investment in targeted marketing campaigns, sales force training and enablement, and supply chain logistics to capitalize on the new product approval.
biowearable sensor
Gross margin declined in Q2 2026 due to acquisition costs and inflation.
Gross margin percentage decreased from 52.7% to 52.5% YoY, attributed to amortization from the Exact Sciences acquisition and higher costs.
52.5%
Gross profit margin percentage for Q2 2026
Sales in Electrophysiology and Rhythm Management grew 13.0% and 12.1% respectively, driven by strong performance outside the U.S.
13%
Sales increase in Electrophysiology, excluding foreign exchange impact
leadless pacemakersablation catheters
Gross profit margin squeezed by the "unfavorable impact of higher costs."
Abbott's gross profit margin declined in Q2 2026 compared to the prior year, explicitly due to higher costs.
-0.2%
Year-over-year change in gross profit margin percentage points (52.7% to 52.5%)
- SEC EDGAR
10-Q
Filed · 5 signals
Abbott repays $1.4B of debt in Q1 2026 following Exact Sciences acquisition
After acquiring Exact Sciences, Abbott assumed $2.8B in debt and immediately repaid half ($1.4B), signaling a focus on deleveraging and rapid financial integration.
$1.4B
Amount of debt repaid in March 2026 that was assumed from the Exact Sciences acquisition.
Exact Sciences
Showing 10 of 14 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
Abbott earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Committing to massive R&D investment for future growth pipeline.CEO is funding nearly 200 clinical trials and initiating several pivotal trials for future blockbuster products, indicating a large, sustained budget for clinical and product development vendors. | |
| Investing in AI for interventional cardiology pre-procedure planning.A recent acquisition of an AI imaging software company highlights a direct investment in AI/ML to enhance their structural heart offerings, creating opportunities for other AI and data-related vendors. | |
| Experiencing significant headwinds in China diagnostics due to pricing and volume pressures.Leadership explicitly identified challenging market conditions in China, particularly from Volume-Based Procurement (VBP), as a major headwind for the core lab diagnostics business. This has negatively impacted both price and volume, representing a significant pain point for one of their larger business units in the region. | |
| Facing gross margin pressure from tariffs, driving focus on cost mitigation.Both the CEO and CFO highlighted that tariffs are negatively impacting gross margins, creating a clear cost pressure. The company has dedicated "gross margin improvement teams" to mitigate these effects, indicating a strong focus on operational efficiency and cost-saving initiatives. | |
| Investing in deep EMR integration with Epic to accelerate CGM adoption.To overcome slower CGM adoption among primary care physicians, the company is investing in a turnkey, full integration into the Epic EMR system. This digital initiative aims to solve a key workflow pain point for clinicians and drive deeper penetration of their diabetes technology. | |
| Anticipating intensified competition in the PFA ablation market by 2026.The CEO confirmed that by 2026, all four major manufacturers will have PFA (Pulsed Field Ablation) catheters on the market. This signals an increasingly crowded and competitive landscape, heightening the need for product differentiation and a strong commercial strategy. |
Signal API · MCP
Track Abbott with the Signal API
One POST /v1/companies/enrich call with abbott.com returns Abbott 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"abbott.com","signal_types":["sec-10q"],"limit":20}'Same industry
10-Q at related companies
Questions about Abbott 10-Q
When did Abbott file its latest 10-Q?
What did Abbott disclose in its latest 10-Q?
What did Abbott say on its recent earnings calls?
Where can I read Abbott's 10-Q filing?
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .